The Food and Drug Administration has released information about Hospira’s announcement of a batch of Morphine Sulfate Injections which has been improperly measured and labeled and has thus had to be recalled.
The recall was initiated following reports from a customer who received syringes with more than the labeled one milliliter dose of the morphine. The batch in question was distributed in January and sent to a limited number of hospitals, as well as wholesalers, throughout ten states in various parts of the country. The morphine is injected via a Carpuject syringe, but the actual product comes in a glass cartridge that has been prefilled with the incorrect amount of morphine. There are ten ready-to-go Morphine Sulfate Carpujects in each Slim-Pak tamper detection box. The affected items expire April 1 of next year and come in lot 10830LL.
The FDA and Hospira are taking the issue seriously because of the dangers present when morphine or any other opioids are used in amounts that exceed what has been recommended. Things like low blood pressure and slowed breathing known as respiratory depression can threaten the safety of the consumer and even lead to death.
Hospira is asking hospitals and wholesalers that have the item in their inventory to quarantine the products and contact Stericycle to receive return and exchange instructions. There have yet to be any reports of a consumer experiencing an adverse reaction.
As a personal injury lawyer in Roseville, I’m disappointed to see such a critical medicine pose a danger to the very consumers who rely on it. I’m hoping as a Burlingame personal injury attorney that the issue gets corrected before an overdose can occur.